Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia

Blood Cells, Molecules, and Diseases

Volumn 54, Issue 1, 2015, Pages 132-138

  Arora, Mansi ^a   Kaul, Deepak ^a   Varma, Neelam ^a   Marwaha, R K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

CYLD cleavage; Human PBMCs; MALT1; Pediatric T ALL; Transformation

Indexed keywords

DEUBIQUITINASE; PROTEIN CYLD; PROTEIN MALT1; UNCLASSIFIED DRUG; CASPASE; CYLD PROTEIN, HUMAN; MALT1 PROTEIN, HUMAN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL LINEAGE; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYLD GENE; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE; ADOLESCENT; CHILD; FEMALE; GENETICS; MALE; METABOLISM; PRESCHOOL CHILD; PROTEIN PROCESSING; TUMOR CELL CULTURE;

ADOLESCENT; CASPASES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; NEOPLASM PROTEINS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN MODIFICATION, TRANSLATIONAL; PROTEOLYSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84927098071     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2014.07.008     Document Type: Article

References (19)

1. Espinosa L., Cathelin S., D'Altri T., Trimarchi T., Statnikov A., Guiu J., et al. The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell 2010, 18:268-281. 10.1016/j.ccr.2010.08.006.
2. Aster J.C., Blacklow S.C., Pear W.S. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J. Pathol. 2011, 223:262-273. 10.1002/path.2789.
3. Kovalenko A., Chable-Bessia C., Cantarella G., Israël A., Wallach D., Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003, 424:801-805. 10.1038/nature01802.
4. Moss S.F., Blaser M.J. Mechanisms of disease: inflammation and the origins of cancer. Nat. Clin. Pract. Oncol. 2005, 2:90-97. (quiz 1 p following 113). 10.1038/ncponc0081.
5. Reiley W.W., Zhang M., Jin W., Losiewicz M., Donohue K.B., Norbury C.C., et al. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat. Immunol. 2006, 7:411-417. 10.1038/ni1315.
6. Hachmann J., Snipas S.J., van Raam B.J., Cancino E.M., Houlihan E.J., Poreba M., et al. Mechanism and specificity of the human paracaspase MALT1. Biochem. J. 2012, 443:287-295. 10.1042/BJ20120035.
7. Staal J., Driege Y., Bekaert T., Demeyer A., Muyllaert D., Van Damme P., et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J. 2011, 30:1742-1752. 10.1038/emboj.2011.85.
8. Sun S.-C. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 2010, 17:25-34. 10.1038/cdd.2009.43.
9. Sharma M., Sharma S., Arora M., Kaul D. Regulation of cellular cyclin D1 gene by arsenic is mediated through miR-2909. Gene 2013, 522:60-64. 10.1016/j.gene.2013.03.058.
10. Williams J.R. The Declaration of Helsinki and public health. Bull. World Health Organ. 2008, 86:650-652. 10.2471/BLT.08.050955.
11. Stempin C.C., Chi L., Giraldo-Vela J.P., High A.A., Häcker H., Redecke V. The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)-dependent NF-κB activation. J. Biol. Chem. 2011, 286:37147-37157. 10.1074/jbc.M111.263384.
12. Massoumi R., Chmielarska K., Hennecke K., Pfeifer A., Fässler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006, 125:665-677. 10.1016/j.cell.2006.03.041.
13. Brummelkamp T.R., Nijman S.M.B., Dirac A.M.G., Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 2003, 424:797-801. 10.1038/nature01811.
14. Kovalenko A., Chable-Bessia C., Cantarella G., Israël A., Wallach D., Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003, 424:801-805. 10.1038/nature01802.
15. Jost P.J., Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707. 10.1182/blood-2006-07-025809.
16. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436. 10.1038/nature04870.
17. Baeuerle P.A., Henkel T. Function and activation of NF-kappaB in the immune system. Annu. Rev. Immunol. 1994, 12:141-179. 10.1146/annurev.iy.12.040194.001041.
18. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444. 10.1038/nature07205.
19. Rauch D., Gross S., Harding J., Bokhari S., Niewiesk S., Lairmore M., et al. T-cell activation promotes tumorigenesis in inflammation-associated cancer. Retrovirology 2009, 6:116. 10.1186/1742-4690-6-116.